Navigation Links
Idenix Reports Positive Interim Data for HCV Nucleotide Inhibitor, IDX184
Date:1/9/2012

CAMBRIDGE, Mass., Jan. 9, 2012 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from a 12-week phase IIb clinical trial of IDX184, the Company's lead product candidate for the treatment of hepatitis C virus (HCV) infection.  IDX184, a pan-genotypic oral nucleotide polymerase inhibitor, has demonstrated a high barrier to resistance in vitro and potent antiviral activity in both preclinical and clinical studies.

IDX184 Phase IIb Study Design
In July 2011, the Company initiated enrollment of treatment-naive genotype 1 HCV-infected patients into a randomized, double-blind, parallel group phase IIb clinical trial of IDX184.  The study features two treatment arms, either 50 mg or 100 mg of IDX184 administered once-daily for 12 weeks, each arm in combination with pegylated interferon and ribavirin (PegIFN/RBV). Study objectives include safety and tolerability, and antiviral activity endpoints.

IDX184 Phase IIb Interim Study Results
The first 31 patients have completed 28 days of treatment, and the interim data have shown that IDX184 was well-tolerated and that there were no serious adverse events associated with therapy. The side effect profile was consistent with that seen with PegIFN/RBV. The independent DSMB has reviewed the data for the first 31 patients and has recommended continuing enrollment of the study. The Company has submitted the interim data, along with the DSMB's recommendations, to the U.S. Food and Drug Administration (FDA) and is requesting the continuation of this study and removal of the partial clinical hold for IDX184.

RVR findings demonstrated that 73% of patients in the 100 mg IDX184 arm (n=15) and 63% in the 50 mg arm (n=16) had undetectable
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Idenix Reports Advancement of HCV Development Pipeline
2. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
3. Idenix Pharmaceuticals to Present at Three Upcoming Investor Conferences
4. Idenix to Host Conference Call Discussing Second Quarter and Six Month 2011 Financial Results
5. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results
6. Idenix Pharmaceuticals to Hold an Investor/Analyst Day Event on October 30, 2010
7. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV
10. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
11. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Applying a well-known optical phenomenon called thin-film interference, ... demonstrated the ability to "paint" ultra-thin coatings onto ... for making future, flexible electronic devices, creating advanced ... rocket ships and spacecraft with extremely lightweight decorative ... water, it becomes iridescent, revealing a myriad of ...
(Date:9/30/2014)... analog of one of nature,s most efficient light-harvesting ... led by Alejandro Briseno of the University of ... developing long-sought polymer architecture to boost power-conversion efficiency ... devices. , Briseno, with colleagues and graduate ... University and Dresden University of Technology, Germany, report ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... and segments with highest potential revenues Do you ... updated report gives you revenue predictions for those ... For those therapies you find financial data, R&D ... analysis you get sales forecasts to 2024 at ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... used to kill nematodes. Nematodes are microscopic parasitic ... soil, water, and inside other plants and animals. ... high volatility or other properties promoting migration through ... contain more than 1,000 plant-parasitic nematodes. With more ...
Breaking Biology Technology:Taking thin films to the extreme 2Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2
... Canada, Oct. 14 ProtoKinetix (OTC,Bulletin Board: ... research,development and commercialization of patented anti-aging glycopeptides,(AAGPs(TM)), ... OTC Financial,Network (OTCFN), a division of National ... shareholder awareness campaign., "ProtoKinetix, AAGP(TM) platform ...
... SOMERSET, N.J., Oct. 14 Alfacell Corporation,(Nasdaq: ACEL ... quarter,and fiscal year ended July 31, 2008., The ... or $0.06,per basic and diluted common share, for the ... loss of approximately $2.4 million, or $0.05 per,basic and ...
... and Company,(NYSE: LLY ) announced today that its ... for all outstanding,shares of ImClone Systems Incorporated (Nasdaq: ... in cash. Lilly and ImClone previously announced that they ... ImClone., The Board of Directors of ImClone has ...
Cached Biology Technology:ProtoKinetix Partners with OTC Financial Network to Increase Shareholder Base 2ProtoKinetix Partners with OTC Financial Network to Increase Shareholder Base 3Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results 2Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results 3Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results 4Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results 5Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share 2Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share 3Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share 4
(Date:9/30/2014)... can live in almost any aquatic environment on Earth, ... many species are pushed to the limit. The amount ... prove critical for how different species cope in the ... University of Gothenburg, published in the scientific journal ... change continues apace thanks to increasing levels of greenhouse ...
(Date:9/30/2014)... urban and farm runoff in Hawaii is causing tumors ... , The study, published Tuesday in the peer-reviewed open-access ... runoff ends up in algae that the turtles eat, ... flippers and internal organs. , Scientists at Duke University, ... Atmospheric Administration (NOAA) conducted the study to better understand ...
(Date:9/30/2014)... Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich report that ... cells more sensitive to chemotherapeutic drugs. They have ... a new target for anti-tumor agents. , ... Professor Stephan Sieber of the Technische Universitt Mnchen ... a potential new weapon in the fight against ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Cancer therapy: Driving cancer cells to suicide 2
... A new study led by scientists at the ... and Policy and the Rosenstiel School of Marine and ... respond to stress from catch-and-release fishing. The results revealed ... sharks were by far the most vulnerable to fighting ...
... study published in Cell by the teams ... in Biomedicine (IRB Barcelona) and the Institute of Molecular ... at the University of Wageningen, in the Netherlands, unravels ... activate multiple vital plant functions through various gene transcription ...
... say they have opened the window on the natural process of ... could be used to advance therapies for bone fractures and disease. ... the Feb. 13 issue of the journal Cell Reports , ... to allow adult zebra fish to perfectly replace bones lost upon ...
Cached Biology News:New study examines the effects of catch-and-release fishing on sharks 2Scientists unveil a molecular mechanism that controls plant growth and development 2Zebra fish fins help Oregon researchers gain insight into bone regeneration 2
... Certify products ATP-Free using Mo Bio ... sensitive ATP-Free certification service that will allow you ... level of accuracy and enable you to deliver ... Mo Bios ATP detection limit is 3.5 ...
... Microarrays: Biomedical Photometrics Inc. (Waterloo, Ontario, Canada) ... have collaborated to develop a fluorescence reader ... The DNAscope AT is based on BPIs ... automatically reads up to six ArrayTubes in ...
... a comprehensive kinase analysis service utilizing ... peptide microarrays synthesized on Paraflo microfluidic ... quantitative measurement of kinase kinetic activities, ... service includes preparation of your kinase ...
... The JNK (c-Jun NH2-terminal kinase) ... three identified MAP kinase pathways in ... response to environmental stress, is associated ... itself, and is implicated in the ...
Biology Products: